⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
PPLPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.5
| Stock Code | PPLPHARMA | Market Cap | 19,021 Cr. | Current Price | 143 ₹ | High / Low | 241 ₹ |
| Stock P/E | 25.8 | Book Value | 58.2 ₹ | Dividend Yield | 0.10 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 159 ₹ | DMA 200 | 181 ₹ |
| Chg in FII Hold | -0.61 % | Chg in DII Hold | 0.79 % | PAT Qtr | 151 Cr. | PAT Prev Qtr | 196 Cr. |
| RSI | 35.1 | MACD | -5.42 | Volume | 29,93,700 | Avg Vol 1Wk | 46,37,699 |
| Low price | 135 ₹ | High price | 241 ₹ | PEG Ratio | 1.16 | Debt to equity | 0.12 |
| 52w Index | 8.04 % | Qtr Profit Var | 27.4 % | EPS | 5.39 ₹ | Industry PE | 27.6 |
📊 Technical Analysis
- Chart Patterns: Stock is trading below both 50-DMA (₹159) and 200-DMA (₹181), showing weakness and downtrend continuation.
- Moving Averages: Current price ₹143 is under both DMAs, confirming bearish bias.
- RSI: 35.1 — oversold territory, potential for short-term bounce.
- MACD: -5.42 — bearish crossover, momentum weak.
- Bollinger Bands: Price near lower band, suggesting possible mean reversion.
- Volume Trends: Current volume (29.9L) below 1-week average (46.3L), showing reduced participation.
📈 Momentum & Signals
- Short-term Momentum: Weak, oversold RSI may trigger bounce.
- Entry Zone: ₹135–₹143 (support levels).
- Exit Zone: ₹159–₹181 (resistance levels).
- Trend Status: Stock is consolidating with bearish bias.
✅ Positive
- PEG ratio of 1.16 suggests fair valuation relative to growth.
- Low debt-to-equity (0.12), financially stable.
- DII holdings increased (+0.79%), showing domestic institutional support.
⚠️ Limitation
- Weak ROCE (12.4%) and ROE (9.74%), showing limited efficiency.
- High volatility with sharp decline from 52-week high (₹241).
- Technical momentum weak below moving averages.
📰 Company Negative News
- Quarterly PAT dropped (₹151 Cr vs ₹196 Cr previous quarter).
- FII holdings decreased (-0.61%), showing reduced foreign investor confidence.
🌟 Company Positive News
- Quarterly profit variance +27.4% YoY indicates growth momentum.
- DII stake increased, showing domestic institutional support.
🏭 Industry
- Industry P/E at 27.6, slightly higher than company’s P/E (25.8), suggesting PPL Pharma is fairly valued relative to peers.
- Pharmaceutical sector remains resilient with steady demand outlook.
🔎 Conclusion
- Stock is consolidating near support with weak momentum.
- Short-term traders may consider entry near ₹135–₹143 with exit around ₹159–₹181.
- Medium-term investors should be cautious due to weak efficiency metrics despite fair valuation.